Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care
暂无分享,去创建一个
H. Kennecke | Siddharth Singh | L. Fishbein | J. Pasieka | J. Del Rivero | Josh Mailman | J. A. Chan | Micheal W Radow | Sarah Creed | Jennifer Zuar | Jaydira Del Rivero
[1] B. Niederle,et al. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? , 2021, Current Oncology Reports.
[2] A. La Salvia,et al. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. , 2021, Comprehensive psychiatry.
[3] D. Fraker,et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma , 2021, Pancreas.
[4] J. Potter,et al. Palliative Sedation, Compassionate Extubation, and the Principle of Double Effect: An Ethical Analysis , 2021, The American journal of hospice & palliative care.
[5] Siming Jia,et al. A case–control study , 2021 .
[6] A. Trojani,et al. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors , 2020, Nutrition and cancer.
[7] D. Metz,et al. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. , 2020, Pancreas.
[8] E. Bruera,et al. Recommendations for Palliative and Hospice Care in NCCN Guidelines for Treatment of Cancer. , 2020, The oncologist.
[9] J. Hallet,et al. Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors , 2020, World Journal of Surgery.
[10] D. Metz,et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.
[11] E. Bruera,et al. Redefining Palliative Care—A New Consensus-Based Definition , 2020, Journal of pain and symptom management.
[12] E. Bruera,et al. Models of Palliative Care Delivery for Patients With Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Bennett,et al. Practice review: Evidence-based and effective management of pain in patients with advanced cancer , 2020, Palliative medicine.
[14] S. Singh,et al. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. , 2019, The oncologist.
[15] J. Hallet,et al. Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes , 2019, Annals of Surgical Oncology.
[16] J. Wills,et al. Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] J. Pratschke,et al. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract , 2018, Reviews in Endocrine and Metabolic Disorders.
[18] D. Metz,et al. Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS) , 2018, Neuroendocrinology.
[19] Y. Mineur,et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice , 2018, Neuropsychopharmacology.
[20] M. Spampatti,et al. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important , 2018, Reviews in Endocrine and Metabolic Disorders.
[21] P. Lapuerta,et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial , 2018, Endocrine-related cancer.
[22] P. Ma,et al. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas , 2017, Neoplasia.
[23] Shouhao Zhou,et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.
[24] D. Meier,et al. Defining Advance Care Planning for Adults: A Consensus Definition From a Multidisciplinary Delphi Panel. , 2017, Journal of pain and symptom management.
[25] H. Sorbye,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents , 2017, Neuroendocrinology.
[26] E. Wolin,et al. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors , 2017, Pancreas.
[27] B. Judson,et al. Treatment delay and facility case volume are associated with survival in early‐stage glottic cancer , 2017, The Laryngoscope.
[28] P. Hellman,et al. Clinical signs of fibrosis in small intestinal neuroendocrine tumours , 2017, The British journal of surgery.
[29] C. Stanciu,et al. Loperamide, the “Poor Man’s Methadone”: Brief Review , 2017, Journal of psychoactive drugs.
[30] V. C. Kok,et al. Management of Hypoglycemia in Nondiabetic Palliative Care Patients: A Prognosis-Based Approach , 2016, Palliative care.
[31] R. Riechelmann,et al. Complications from carcinoid syndrome: review of the current evidence , 2016, Ecancermedicalscience.
[32] E. Bruera,et al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review , 2016, The oncologist.
[33] M. Pavel,et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs , 2016, Journal of global oncology.
[34] G. Lemmens,et al. May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report , 2016, Acta oncologica.
[35] L. Ellegård,et al. Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET) , 2016, European Journal of Clinical Nutrition.
[36] Roger Chou,et al. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[37] E. D. de Vries,et al. Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor , 2015, Neuroendocrinology.
[38] Richard S Levene,et al. Hypoglycemia management in nondiabetic adults at the end of life #291. , 2015, Journal of Palliative Medicine.
[39] C. Peruselli. [Early palliative care]. , 2015, Recenti progressi in medicina.
[40] Mark T Hegel,et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] H. Kennecke,et al. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors , 2015, Cancer Medicine.
[42] Feng Yang,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[43] B. Boulay,et al. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. , 2014, World journal of gastroenterology.
[44] Allan Donner,et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial , 2014, The Lancet.
[45] W. Drake,et al. Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. , 2010, QJM : monthly journal of the Association of Physicians.
[46] I. Modlin,et al. article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .
[47] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] S. Connor. Development of Hospice and Palliative Care in the United States , 2008, Omega.
[49] K. Iwasaki,et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. , 2007, Journal of pain and symptom management.
[50] Xinjun Li,et al. Incidence trends and risk factors of carcinoid tumors , 2001, Cancer.
[51] J. Rastad,et al. Method for Dissection of Mesenteric Metastases in Mid-gut Carcinoid Tumors , 2000, World Journal of Surgery.
[52] J. Ajani,et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] G. Gill,et al. Diazoxide treatment for insulinoma: a national UK survey. , 1997, Postgraduate medical journal.
[54] L. Kvols,et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.
[55] J. Farndon,et al. Diazoxide in the management of patients with insulinoma , 1986, World Journal of Surgery.
[56] E. Keat,et al. Carcinoid Heart Disease , 1974, Proceedings of the Royal Society of Medicine.
[57] A. Vinik,et al. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. , 2018, The oncologist.
[58] Kjell Öberg,et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Thomas J. Smith,et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Eva Segelov,et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors , 2017, Pancreas.
[61] K. Oberg,et al. The management of neuroendocrine tumours: current and future medical therapy options. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).
[62] M. Caplin,et al. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. , 2005, Best practice & research. Clinical gastroenterology.
[63] G. Hartmann. The Role of Diet , 1982 .
[64] A. Bornstein,et al. Carcinoid Tumors , 2006 .